TRIUMPH-1 is the Phase 3 registrational obesity trial that anchors Eli Lilly's NDA filing for retatrutide — the company's first-in-class GIP/GLP-1/glucagon triple-receptor agonist. The trial randomized 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes, to placebo or retatrutide 4 mg, 9 mg, or 12 mg over 80 weeks of treatment. Topline data released May 21, 2026 showed mean weight loss of 19.0%, 25.9%, and 28.3% across the three doses versus 2.2% on placebo; 45.3% of participants on 12 mg reached ≥30% weight loss — bariatric-surgery territory. A 104-week extension in the BMI ≥35 subgroup pushed mean weight loss to 30.3% (85.0 lbs) on 12 mg.
The safety profile carried discontinuation rates of 4.1%, 6.9%, and 11.3% on 4, 9, and 12 mg versus 4.9% placebo. Transient ALT elevations that surfaced in TRIUMPH-4 reappeared and normalized by week 24, consistent with hepatic triglyceride mobilization rather than hepatotoxicity. Liver fat dropped >80% on the 8-12 mg arm. Full TRIUMPH-1 data presentation is scheduled for ADA 2026 in New Orleans (June 5-8).
Stories here cover the Phase 3 readout, the broader TRIUMPH program (TRIUMPH-2 obesity + T2D and TRIUMPH-3 obesity + cardiovascular disease, both reading out later in 2026; TRIUMPH-OUTCOMES cardiovascular 10,000-patient trial reading out 2027), the NDA filing timeline, and the competitive response from Novo Nordisk and the broader incretin pipeline. See #retatrutide, #eli-lilly, and #triple-agonist for adjacent threads.
Eli Lilly (NYSE: LLY) clarified that the retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple agonist peptide) regulatory submission timeline was pushed from end-2026 to Q1 2027 as the company continues gathering manufacturing and quality control data required for the FDA Biologics License Application. TRIUMPH-1 (obesity without type 2 diabetes) Phase 3 readout updated documented 28.3% mean weight loss at 80 weeks on the 12 mg weekly injection arm in 2,339 participants, the largest weight-loss figure reported in any Phase 3 obesity trial to date. Combined with TRIUMPH-2 (obesity plus type 2 diabetes at up to 20.8% weight loss and 1.6 percentage point HbA1c reduction in 1,152 participants), TRIUMPH-3 (additional confirmatory data), and TRIUMPH-4 (obesity plus knee osteoarthritis at 28.7% weight loss and 75.8% WOMAC pain reduction), the retatrutide package now anchors four major indication frames. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. The Q1 2027 filing timeline shift is a modest delay from prior end-2026 signaling but reflects manufacturing-scale challenges typical of peptide APIs at the projected multi-billion-dollar commercial demand level (semaglutide and tirzepatide combined are already at roughly $80 billion annual revenue). Potential FDA approval expected in 2027 to 2028 following the standard 10-month review or 6-month priority review if a Priority Review Voucher (PRV) is deployed. Retatrutide will likely reshape the entire obesity drug class ceiling on the injectable side once approved.
Eli Lilly (NYSE: LLY) plans to submit a Biologics License Application (BLA) for retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple hormone receptor agonist peptide) to the FDA in Q1 2027 following the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 readouts. TRIUMPH-2 (obesity and type 2 diabetes) enrolled 1,152 adults and documented up to 20.8% mean weight loss and 1.6 percentage point HbA1c reduction at 68 weeks. TRIUMPH-3 confirmed similar efficacy profiles across an additional patient population. Combined with the earlier readouts (TRIUMPH-1 in obesity without diabetes at 28.7% mean weight loss at 68 weeks at the 12 mg dose, and TRIUMPH-4 in obesity plus knee osteoarthritis at 28.7% weight loss with 75.8% reduction in WOMAC pain scores), the retatrutide package now covers four major indication frames with consistent efficacy. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. Potential FDA approval is expected in 2027-2028, positioning retatrutide to set the new weight-loss ceiling in the obesity drug class at 28.7% (versus tirzepatide's 25.5% and semaglutide's 15% in the current approved landscape).
Eli Lilly (NYSE: LLY) is expected to submit retatrutide (once-weekly injectable triple GLP-1/GIP/glucagon receptor agonist peptide) to the FDA in late 2026 or 2027 following the seven Phase 3 TRIUMPH-program readouts expected across 2026. Program status: TRIUMPH-1 in obesity met primary endpoint with 28.7% mean weight loss at 68 weeks at the 12 mg dose; TRIUMPH-4 in obesity plus knee osteoarthritis documented 28.7% weight loss and 75.8% reduction in WOMAC pain scores with more than 1 in 8 retatrutide-treated patients completely free from knee pain at study end. Additional Phase 3 readouts expected across 2026 in type 2 diabetes, obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic indications. If the full TRIUMPH package supports approval, retatrutide would be the highest-magnitude weight loss obesity drug on record (extending the ceiling from tirzepatide's 25.5% at 84 weeks in REDEFINE 4 head-to-head to 28.7% in TRIUMPH-4). The triple-receptor mechanism activates GLP-1 (appetite suppression via hypothalamic pathways), GIP (adipose tissue effects plus central appetite contribution), and glucagon (hepatic effects plus thermogenesis), producing broader tissue coverage than dual-agonist tirzepatide or amylin-plus-GLP-1 CagriSema. Approval is anticipated in 2027-2028 and would reshape the competitive dynamics for the entire obesity drug class, with substantial implications for Novo Nordisk's franchise defense strategy following the August 2026 broker downgrade and Wegovy 7.2 mg higher-dose FDA review submission.
The full TRIUMPH-1 safety dataset clarified the retatrutide dysesthesia signal: 20.9% of patients on 12 mg reported tingling, tenderness, or altered sensation, versus 8.8% at 9 mg and 0.7% on placebo. The signal is dose-dependent, generally mild to moderate, and Lilly says it is being monitored across all ongoing TRIUMPH trials. The data sit alongside the arrhythmia signal (7/403 retatrutide, 3 MACE versus 0 placebo) that STAT flagged on June 6 and now constitute the field's main retatrutide-specific safety conversation.
At Saturday's Phase 3 retatrutide symposium, Lilly presented the full TRIUMPH-1 dataset in 2,339 adults with obesity or overweight without diabetes. Mean weight loss reached 28.3% (70.3 lbs) at 12 mg over 80 weeks, with 45.3% of 12 mg patients reaching at least 30% loss; in a BMI ≥35 extension, the 12 mg arm hit 30.3% (85.0 lbs) at 104 weeks. Cardiometabolic side effects included up to 41.0% triglyceride drop, 24.2% non-HDL drop, 12.3 mmHg systolic blood pressure drop, and 24.1 cm waist reduction. The 4 mg dose still produced 19.0% weight loss with discontinuation below placebo.
The 86th ADA Scientific Sessions opened June 5 in New Orleans with the late-breaker embargo lifting at 6:30 p.m. CT. Saturday's June 6 Phase 3 retatrutide symposium brings full TRIUMPH-1 (28.3% mean weight loss at 80 weeks) and TRANSCEND-T2D-1 data; Monday's June 8 orforglipron ACHIEVE symposium covers head-to-head data against oral semaglutide and dapagliflozin; Roche, Novo Nordisk, and Boehringer all run investor events the same day.
The Sunday coverage cycle on Lilly's Thursday TRIUMPH-1 readout settled into broadly favorable consensus. Leerink's David Risinger characterized the data as 'raising the bar for future novel obesity drug developers'; RBC Capital's Trung Huynh framed it as a 'clean win for Lilly'; Dan Skovronsky (Lilly CSO) called 30% weight loss 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' Mainstream press coverage — NPR, BioPharma Dive, CNBC, Good Morning America — uniformly led with the bariatric-surgery-territory framing (45.3% of 12 mg participants reaching ≥30% weight loss). The dysesthesia signal (12.5% at 12 mg) registered in pharma-industry coverage and analyst commentary but received minimal mainstream-press attention. The TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + CVD) readouts later in 2026 are the next inflection points; the NDA filing follows in Q4 2026 or Q1 2027.
Day-after analyst commentary on Lilly's Thursday TRIUMPH-1 topline split favorably across major sell-side and management voices. Leerink Partners' David Risinger wrote that 'tolerability and substantial weight loss shown by retatrutide is raising the bar for future novel obesity drug developers,' a framing that lands at the higher end of the analyst spectrum after William Blair's tolerability-confined assessment Thursday. RBC Capital Markets' Trung Huynh characterized the readout as a 'clean win for [Lilly]' citing the clean safety profile plus best-in-class efficacy across all three doses. Dan Skovronsky, Lilly's chief scientific and product officer, told CNBC over the weekend that 30% weight loss in the BMI ≥35 extension is 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' The Saturday-Sunday news-cycle handling has settled into broadly favorable territory.
The TRIUMPH-1 dysesthesia signal (skin tingling, paresthesia-like sensations) that BMO Capital flagged Thursday merits a mechanistic look. The signal appeared in 12.5% of participants on retatrutide 12 mg in TRIUMPH-1, but was NOT reported in the Phase 2 retatrutide program. TRIUMPH-4 (December 2025 readout) recorded dysesthesia in approximately 20.9% of participants on the highest dose — most cases mild and resolving during ongoing treatment. The mechanistic explanation is tied to retatrutide's glucagon-receptor activation: glucagon signaling drives small-fiber sensory neuropathy patterns through downstream effects on c-AMP-mediated nociceptor sensitization. The pattern is dose-dependent (4 mg essentially no signal, 9 mg modest, 12 mg the peak). The clinical question is whether dysesthesia stays mild and reversible at commercial scale or whether a small fraction of patients develop persistent or more severe sensory disturbances. The signal is the differentiator from tirzepatide (no glucagon arm) and semaglutide (no glucagon, no GIP).
TRIUMPH-1 reported 45.3% of participants on the 12 mg dose reached ≥30% weight loss — historically the threshold associated with bariatric surgery outcomes (sleeve gastrectomy averages 25-30%, Roux-en-Y gastric bypass 30-35% at 1-2 years). The data point is the most consequential single statistic from the TRIUMPH-1 readout because it reframes the bariatric-referral conversation that anchors severe-obesity care. For patients with BMI 35-40 with comorbidities (the broadest bariatric-eligible population), pharmacological 30% weight loss closely approximates the surgical outcome without the irreversible anatomical changes, perioperative mortality (~0.1% gastric bypass), nutritional-deficiency monitoring requirements, or psychiatric adjustment patterns that follow bariatric procedures. Bariatric surgery centers' patient-referral volume began softening in 2024-2025 as Wegovy and Zepbound scaled; retatrutide's TRIUMPH-1 data accelerates that trend. The American Society for Metabolic and Bariatric Surgery (ASMBS) and the Obesity Society will likely revisit referral algorithms ahead of retatrutide's late-2027 launch.
Day-after analyst reaction to Lilly's May 21 TRIUMPH-1 topline split between efficacy enthusiasm and tolerability caution. LLY shares rose roughly 1% in Thursday premarket trading. William Blair noted that retatrutide's 11.3% discontinuation rate on 12 mg plus the dysesthesia signal (skin tingling, 12.5% of 12 mg participants — a finding not reported in Phase 2 data) probably confines the drug to higher-BMI patient populations, with tirzepatide remaining the volume agent at the moderate-BMI tier. BMO Capital Markets specifically flagged the dysesthesia signal as worth monitoring in subsequent readouts and the TRIUMPH-4 follow-on detail. Manak Mahmood at Pharma Intelligence framed the data as 'very impressive' but noted ADA 2026 full data presentation in two weeks will be critical for the obesity-market positioning. The GI side-effect profile at 12 mg — nausea 42.4%, vomiting 25.3%, diarrhea 32.0% — is the tolerability gap that prescribers will weigh against the efficacy gain over tirzepatide.
Eli Lilly announced TRIUMPH-1 topline results May 21 from the 80-week Phase 3 registrational trial of retatrutide — a first-in-class GIP/GLP-1/glucagon triple-receptor agonist — in 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes. Mean body weight loss was 28.3% (70.3 lbs) at 12 mg, 25.9% at 9 mg, and 19.0% at 4 mg, all versus 2.2% on placebo. All three doses met the primary and key secondary endpoints. 45.3% of participants achieved ≥30% weight loss — bariatric-surgery territory. A 104-week extension in adults with baseline BMI ≥35 saw mean weight loss reach 30.3% (85.0 lbs) on 12 mg. Full data presentation is scheduled for ADA 2026 in New Orleans (June 5-8). Lilly's NDA filing follows the TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + established cardiovascular disease) readouts expected later in 2026.
TRIUMPH-1's safety profile landed alongside the efficacy headline. Discontinuation rates due to adverse events were 4.1%, 6.9%, and 11.3% on retatrutide 4 mg, 9 mg, and 12 mg respectively, versus 4.9% on placebo. The most common adverse events were nausea, diarrhea, constipation, and vomiting — generally mild-to-moderate, concentrated during dose escalation, and decreasing over time. The hepatic-enzyme signal that appeared in TRIUMPH-4 (December 2025) reappeared as transient ALT elevations in a subset of participants on 9 mg and 12 mg dosing, normalizing by week 24. Liver fat dropped >80% on 8-12 mg dosing, supporting the interpretation that the transient transaminitis reflects hepatic triglyceride mobilization rather than hepatotoxicity. The 12 mg discontinuation rate at 11.3% sits modestly above tirzepatide 15 mg in SURMOUNT-1 (~7%) and Wegovy 2.4 mg in STEP 1 (~6.5%) — a tolerability gap that prescribers and patients will weigh against the efficacy gain.
Motley Fool's May 17 analysis framed retatrutide — Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist — as the molecule positioned to displace both semaglutide (Wegovy) and tirzepatide (Zepbound) from the obesity therapeutics top spot. The thesis rests on TRIUMPH-1 (general obesity without T2D, 80 weeks, pivotal NDA-supporting trial) and TRIUMPH-2 (obesity + T2D) readouts expected Q2-Q3 2026. TRIUMPH-4 already reported a 28.7% mean weight reduction at the 12 mg dose at 68 weeks — well above the 21% standard Wegovy 2.4 mg and the 22.5% Zepbound 15 mg ceilings. If TRIUMPH-1 confirms the 25%+ weight-loss range, retatrutide's NDA filing follows in late 2026 / early 2027 with approval mid-2027. The full TRIUMPH program runs eight pivotal trials with >5,800 participants plus a separate 10,000-patient cardiovascular outcomes trial reading out in 2027.
Eli Lilly's TRIUMPH program for retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — has TRIUMPH-1 (general obesity without T2D, 80 weeks, 2,007 participants) and TRIUMPH-2 (obesity + T2D) reading out in Q2-Q3 2026. Both are pivotal for the planned NDA filing. The earlier TRIUMPH-4 readout in December 2025 delivered 28.7% mean weight loss at 68 weeks on 12 mg dosing with 75% knee osteoarthritis pain reduction. The full TRIUMPH program runs eight pivotal trials with >5,800 participants total: obesity, T2D, OSA, MASLD, knee OA, cardiovascular outcomes (TRIUMPH-OUTCOMES, ~10,000 patients reading out 2027), and dose-extension studies. A new safety signal noted in Phase 2 — a small uptick in mild-to-moderate hepatic enzyme elevations on 12 mg dosing — will be monitored carefully in Phase 3 readouts. Lilly's $4.5B Lebanon Indiana investment (announced May 6) targets retatrutide manufacturing capacity ahead of the 2027 approval window.